Neurotrope BioSciences moves forward with novel Alzheimer's candidate
Alzheimer's disease start up Neurotrope BioSciences is to proceed to Phase IIb studies of its lead product bryostatin after positive top-line safety data from a Phase IIa trial.
Alzheimer's disease start up Neurotrope BioSciences is to proceed to Phase IIb studies of its lead product bryostatin after positive top-line safety data from a Phase IIa trial.